Bullfrog AI Holdings Reports First Revenue of $33,257 in Q2 2025, Faces Liquidity Challenges

Bullfrog AI Holdings, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $33,257, attributed entirely to collaboration revenue from a single customer agreement. This marks the company's first revenue recognition since its inception, contrasting with the previous fiscal period when no revenue was recorded. The cost of revenue for the same period was $26,735, resulting in a gross profit of $6,522. However, the company continues to operate at a loss, reporting a net loss of $1,448,729 for the quarter, a slight improvement from the net loss of $1,611,646 in the same quarter of 2024.

In terms of operational metrics, Bullfrog AI's total operating expenses decreased to $1,476,195 for the three months ended June 30, 2025, down from $1,681,963 in the prior year. This reduction was primarily due to lower general and administrative expenses, which fell to $995,898 from $1,168,264, and a decrease in research and development costs, which amounted to $480,297 compared to $513,699 in the previous year. The company’s accumulated deficit has now reached approximately $20.3 million, reflecting ongoing challenges in achieving profitability.

Strategically, Bullfrog AI has made significant strides in its business development, including the completion of its first commercial service contract in 2023 and a collaboration agreement with Eleison Pharmaceuticals, a Phase III oncology company. The company has also entered into exclusive worldwide license agreements with prestigious institutions such as Johns Hopkins University and George Washington University for various cancer drug developments. As of June 30, 2025, the company had 10,081,340 shares of common stock issued and outstanding, reflecting its ongoing efforts to raise capital through equity sales.

Despite these developments, the company faces liquidity challenges, with cash and cash equivalents totaling approximately $2.6 million as of June 30, 2025. This amount is insufficient to fund operations for the next year, raising substantial doubt about the company's ability to continue as a going concern. Bullfrog AI plans to seek additional capital through various means, including equity sales and collaborative arrangements, to support its ongoing operations and strategic initiatives.

Looking ahead, Bullfrog AI Holdings, Inc. aims to leverage its proprietary AI/ML platform, bfLEAP™, to enhance drug development processes and improve the success rates of clinical trials. The company is focused on expanding its partnerships and collaborations while continuing to develop its internal drug candidates. However, the management cautions that the ability to execute its strategy is contingent upon securing necessary funding and achieving operational milestones in a challenging market environment.